Major Depressive Disorder

The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for treatment-resistant major depressive disorder has now demonstrated promise for reducing depressive symptoms of bipolar I disorder in an open-label feasibility and safety trial.

Patients with treatment resistant late-life depression are more likely to respond to antidepressants when sleep is sufficient or has improved.

Cognitive symptoms affect between 85% and 94% of patients with major depressive disorder. Despite this prevalence, cognitive dysfunction often remains undertreated and inadequately addressed in routine clinical practice.

Ketamine or ECT? A new study reveals which works best for severe depression—depending on the patient and setting.

Alzamend announced a late 2025 initiation for the phase 2 clinical study of AL001, a novel lithium-delivery system for the treatment of patients with major depressive disorder.

A new transcranial direct current stimulation device received approval from the FDA for an investigational device exemption, prompting a phase 3 trial.

Discover key insights from February’s Special Report on child and adolescent psychiatry, exploring overlooked diagnoses, new research, and the complex impact of social media on youth mental health.

Here are highlights from this week in Psychiatric Times, including updates on the BHV-7000 for bipolar disorder trial and a new study on physician suicide rates.

A recent study found that ketamine and transcranial magnetic stimulation show promise in treating treatment-resistant depression in older adults.

BLP-003, currently being evaluated for treatment-resistant depression and alcohol use disorder, today announced their global phase 2b clinical trial has completed patient enrollment.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Learn more about recent research into adolescent mental health, including a pilot study testing the use of short-term trauma stabilization techniques with escitalopram.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

After a lot of recent positive news for SPN-820, a recent phase 2b study shows the novel antidepressant failed to demonstrate a statistically significant improvement on the primary endpoint of change from baseline.

What are the top 6 disappointing psychopharmacological updates from the past year? We rank the top 6.

Catch up on coverage from the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.

A pooled analysis of two clinical trials highlights AXS-05’s rapid and sustained effectiveness in reducing depressive symptoms, offering a promising new treatment option for major depressive disorder with a manageable safety profile.

A new phase 2 trial reveals a novel antidepressant delivers rapid symptom relief for major depressive disorder, with patients experiencing significant improvement within just hours of their first dose.

New phase 3 data on CYB003 is coming. Learn more about the phase 3 pivotal program here.

Learn more about the latest research on the impact the endocrine system has on major depressive disorder.

Check out these updates on research including major depressive disorder (MDD).

A recent phase 2b trial of GH001 showed promising results for treatment-resistant depression, demonstrating rapid and sustained effects with a favorable safety profile.

What patients are at risk when taking SSRIs?

Check out the pipeline updates from January!

Here are highlights from this week in Psychiatric Times, including FDA news and a look back at Psychiatric Times through the years.

Meditation using immersive virtual reality devices can help alleviate symptoms of major depressive disorder and generalized anxiety disorder.

How should clinicians approach loneliness in elderly patients, and how can technology assist in treatment?

How does affluence impact mental health outcomes?

Neurocrine is initiating a phase 3 study of osavampator for the treatment of adults with major depressive disorder.